Related Experiment Video

Updated: Aug 17, 2026

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

Pulmonary function in patients on long-term, low-dose methotrexate

T J Phillips, P J Wallis, D H Jones

    The British Journal of Dermatology
    |December 1, 1986
    PubMed

    Insights

    Long-term, low-dose methotrexate for psoriasis did not show signs of early lung damage in patients. This study monitored pulmonary function to assess methotrexate

    Area of Science:

    • Dermatology and Pulmonology
    • Pharmacology and Toxicology

    Background:

    • Psoriasis is a chronic inflammatory skin condition.
    • Methotrexate is a common treatment for moderate to severe psoriasis.
    • Concerns exist regarding potential long-term pulmonary toxicity of methotrexate.

    Observation:

    • A cohort of patients undergoing long-term, low-dose methotrexate therapy for psoriasis was evaluated.
    • Pulmonary function tests were systematically performed on study participants.

    Findings:

    • No evidence of early pulmonary damage was detected in patients receiving treatment.
    • Methotrexate, at low doses for psoriasis, appears safe for pulmonary health in the studied cohort.

    Implications:

    • This research suggests a favorable pulmonary safety profile for low-dose methotrexate in psoriasis management.
    • Further long-term studies may be warranted to confirm these findings across diverse patient populations.

    More Related Videos

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis05:45

    A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

    Published on: January 16, 2026

    Related Concept Videos

    COPD: Management Using Bronchodilators and Corticosteroids01:26

    COPD: Management Using Bronchodilators and Corticosteroids

    Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
    Pulmonary Tuberculosis I01:29

    Pulmonary Tuberculosis I

    Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
    Causative Organism
    The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
    Mode of...
    Pulmonary Tuberculosis V01:28

    Pulmonary Tuberculosis V

    Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
    Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
    Chronic Obstructive Pulmonary Disease-V: Management01:29

    Chronic Obstructive Pulmonary Disease-V: Management

    Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
    Smoking Cessation
    Pulmonary Function Tests01:25

    Pulmonary Function Tests

    Pulmonary Function Tests (PFTs)
    Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
    PFTs involve using a spirometer, a...
    Therapeutic Drug Monitoring: Affecting Factors01:29

    Therapeutic Drug Monitoring: Affecting Factors

    Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.